Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 7/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 4/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.32 |
| ▸ | VCP | P55072 | 1/20 | 0.32 |
| ▸ | GCK | P35557 | 3/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | PPARD | Q03181 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3003503 | 0.90 | PRMT5 (0.34) | MCHR1KCNH2ADORA2APRMT5VCP | |
| SCHEMBL3000984 | 0.84 | MCHR1 (0.36) | MCHR1DGAT1KCNH2ADORA2AHRH3 | |
| SCHEMBL3011914 | 0.83 | JAK2 (0.35) | MCHR1KCNH2ADORA2AHRH3PPARD | |
| SCHEMBL3005745 | 0.80 | MCHR1 (0.35) | MCHR1DGAT1KCNH2ADORA2AGCK | |
| SCHEMBL3578441 | 0.76 | PTGES (0.47) | MCHR1DGAT1KCNH2ADORA2ASOAT1 | |
| SCHEMBL3577884 | 0.73 | GCK (0.41) | MCHR1DGAT1KCNH2ADORA2ASOAT1 | |
| SCHEMBL3576199 | 0.71 | PPARG (0.40) | MCHR1DGAT1KCNH2ADORA2APPARD | |
| SCHEMBL3017912 | 0.70 | PPARA (0.37) | MCHR1DGAT1KCNH2ADORA2APPARD | |
| SCHEMBL3006485 | 0.69 | PTGES (0.38) | KCNH2PPARDPPARA | |
| SCHEMBL4700751 | 0.68 | GCK (0.41) | MCHR1DGAT1KCNH2ADORA2ASOAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197687-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2010-08-05 | — | — | US | disclosed |
| EP-1841736-A1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | Biolipox AB (SE) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006077367-A1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMATION | BIOLIPOX AB (SE) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197687-A1 | Indoles Useful in the Treatment of Inflammation | IDO1, IDO2, TPH1 | MCHR1 89/4885DGAT1 4287/4885KCNH2 4299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.